Evidence map›Paper›PMID 39824843›Full record

ArticleCell death discovery2025

pir-hsa-216911 inhibit pyroptosis in hepatocellular carcinoma by suppressing TLR4 initiated GSDMD activation.

Zhouxiang Liao, Lichao Yang, Xiaojing Cheng, Xuejing Huang, Qi Zhang, Daoqiang Wen, Zhenyu Song, Yasi Li, Sha Wen, Yongfeng Li and 4 more

Abstract read
In one paragraph

Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Caspase-1 in cancer and inflammatory diseases: a potential therapeutic target.Apoptosis : an international journal on programmed cell death · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhouxiang Liao *School of Public Health, Guangxi Medical University, Nanning, 530021, China.ORCID http://orcid.org/0000-0003-1295-2917
Lichao Yang *Laboratory Animal Center of Guangxi Medical University, Nanning, 530021, China.
Xiaojing Cheng *School of Public Health, Guangxi Medical University, Nanning, 530021, China.
Xuejing HuangLaboratory Animal Center of Guangxi Medical University, Nanning, 530021, China.
Qi ZhangLaboratory Animal Center of Guangxi Medical University, Nanning, 530021, China.
Daoqiang WenDepartment of Hepatobiliary Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, China.
Zhenyu SongLaboratory Animal Center of Guangxi Medical University, Nanning, 530021, China.
Yasi LiDepartment of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, PA, 17033, USA.
Sha WenLaboratory Animal Center of Guangxi Medical University, Nanning, 530021, China.
Yongfeng LiSchool of Public Health, Guangxi Medical University, Nanning, 530021, China.
Meizhen OuLaboratory Animal Center of Guangxi Medical University, Nanning, 530021, China.
Zhangnan HuangDepartment of Hepatobiliary Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530021, China.
Tianqi LiuDepartment of Hepatobiliary Surgery, Hospital of Guangxi Jiang Bing, Nanning, 530021, China. ljrqt@126.com.
Min HeSchool of Public Health, Guangxi Medical University, Nanning, 530021, China. hemin@gxmu.edu.cn.ORCID http://orcid.org/0000-0002-2735-2474

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81760612
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a global health concern, ranking as the fourth leading cause of cancer-related deaths worldwide. However, the role of piwi-interacting RNAs (piRNAs) in HCC processes has not been extensively explored. Through small RNA sequencing, our study identified a specific piRNA, pir-hsa-216911, which is highly expressed in HCC cells. This overexpression of pir-hsa-216911 promotes HCC cell invasion and inhibits cell death, particularly pyroptosis. Knocking out pir-hsa-216911 led to increased cell pyroptosis activity, resulting in the activation of caspase-1 and GSDMD. Further analysis revealed that pir-hsa-216911 targets and suppresses TLR4, a key gene associated with pyroptosis in HCC. In the Huh7 cell line, pir-hsa-216911 knockout confirmed its role in suppressing the TLR4/NFκB/NLRP3 pathway by silencing TLR4. Knocking out pir-hsa-216911 significantly inhibited the formation of Huh7 xenograft tumor. In HCC patients, pir-hsa-216911 was highly expressed in HCC tumor samples with steatosis, suppressing TLR4 expression and inhibiting GSDMD activation. This study introduces pir-hsa-216911 as a new high-expressing piRNA in HCC, which inhibits pyroptosis by silencing TLR4 to suppress GSDMD activation. These findings have significant implications for HCC molecular subtyping and as a potential target for cancer therapy.

Identifiers

PMID39824843
PMCPMC11742400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.